Literature DB >> 8931276

Immune responses to adenovirus vectors in the nervous system.

M J Wood1, H M Charlton, K J Wood, K Kajiwara, A P Byrnes.   

Abstract

Non-replicating adenovirus vectors are being developed as vehicles for gene transfer into cells of the nervous system. An important requirement for successful gene transfer is the absence of deleterious cytotoxic or inflammatory side effects of the delivery system. Despite offering relatively stable reporter gene expression, currently available adenovirus vectors also elicit immune responses in the brain, both at the site of vector delivery and at synaptically linked distant sites. However, although an anti-viral T-lymphocyte response eliminates the vector and damages local tissue in many peripheral organs, the immune response to adenovirus in the brain is less effective and enables the vector to persist. Nevertheless, in this persistent state the adenovirus vector remains a potential target for a destructive immune response that can also cause local demyelination. The development of strategies to minimize this damaging immune response, through either vector modification or immunomodulation, will be crucial for the future success of genetic therapies in the brain.

Entities:  

Mesh:

Year:  1996        PMID: 8931276     DOI: 10.1016/S0166-2236(96)10060-6

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  26 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Mol Brain Res       Date:  2005-04-18

4.  Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.

Authors:  Carlos Barcia; Christian Gerdes; Wei-Dong Xiong; Clare E Thomas; Chunyan Liu; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Neuron Glia Biol       Date:  2006-11

Review 5.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

6.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

Authors:  Carmen S Peden; Fredric P Manfredsson; Sharon K Reimsnider; Amy E Poirier; Corinna Burger; Nicholas Muzyczka; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

7.  Preferential and bidirectional labeling of the rubrospinal tract with adenovirus-GFP for monitoring normal and injured axons.

Authors:  Xiaofei Wang; George M Smith; Xiao-Ming Xu
Journal:  J Neurotrauma       Date:  2011-03-24       Impact factor: 5.269

Review 8.  Treatment of Parkinson's disease : what's on the horizon?

Authors:  Stacy S Wu; Steven J Frucht
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 9.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

10.  Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes.

Authors:  Yu-feng Zhang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.